Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens

Cancer Research

Volumn 58, Issue 5, 1998, Pages 871-876

  Pacilio, Carmen ^a   Germano, Domenico ^a   Addeo, Raffaele ^a   Altucci, Lucia ^a   Petrizzi, Valeria Belsito ^a   Cancemi, Massimo ^a   Cicatiello, Luigi ^a   Salzano, Salvatore ^b   Lallemand, François ^c   Michalides, Rob J A M ^c   Bresciani, Francesco ^a   Weisz, Alessandro ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; CHLORTETRACYCLINE; CYCLIN D1; FULVESTRANT;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOSTASIS; GENE DOSAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL DIVISION; CHROMOSOMES, HUMAN, PAIR 11; CYCLIN D1; ESTROGEN ANTAGONISTS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; TUMOR CELLS, CULTURED;

EID: 0032031807     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hall, M., and Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. In: G. F. Vande Woude and G. Klein (eds.), Advances in Cancer Research, Vol. 68, pp. 67-108. San Diego, CA: Academic Press, 1996.
2. MacLachlan, T. K., Sang, N., and Giordano, A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr., 5: 127-156, 1995.
3. 1-arrested human breast cancer cells. Oncogene, 12: 2315-2324, 1996.
4. Musgrove, E. A., Hamilton, J. A., Lee, C. S. L., Sweeney, K. J. E., Watts, C. K. W., and Sutherland, R. L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol., 13: 3577-3587, 1993.
5. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J. Biol. Chem., 272: 10882-10894, 1997.
6. Zwijsen, R. M. L., Klompmaker, R., Wientjens, E. B. H. G. M., Kristell, P. M. P., van der Burg, B., and Michalides, R. J. A. M. Cyclin D1 triggers autonomous growth of breast cancer cells by governing cell cycle exit. Mol. Cell. Biol., 16: 2554-2560, 1996.
7. 1 to complete the cell cycle. Proc. Natl. Acad. Sci. USA, 91: 8022-8026, 1994.
8. Buckley, M. F., Sweeney, J. E., Hamilton, J. A., Sini, R. L., Manning, D. L., Nicholson, R. I., deFazio, A., Watts, C. K. W., Musgrove, E. A., and Sutherland, R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene, 8: 2127-2133, 1993.
9. Gillet, C., Fantl, V., Smith, R., Fisher, C., Bartek J., Dickson, C., Barnes, D., and Peters, G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res., 54: 1812-1817, 1994.
10. Bartkova, J., Lukas, J., Muller, H., Lutzhoft, D., Strauss, M., and Bartek, J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer, 57: 353-361, 1994.
11. McIntosh, G. G., Anderson, J. J., Milton, J., Steward, M., Parr, A. H., Thomas, M. D., Henry, J. A., Angus, B., Lennard, T. W. J., and Horne, C. H. W. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11: 885-891, 1995.
12. Michalides, R., Hageman, P., van Tinteren, H., Wientjens, E., Klopmaker, R., and Peterse, J. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 71: 728-734, 1996.
13. Gillet, C., Smith, P., Gregory, W., Richards, M., Millis, R., Peters, G., and Barnes, D. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer, 69: 92-99, 1996.
14. Courjal, F., Louason, G., Speiser, P., Katsaros, D., Zeillinger, R., and Theillet, C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breasts and cyclin E in ovarian cancers. Int. J. Cancer, 69: 247-253, 1996.
15. Frierson, H. F., Jr., Gaffey, M. J., Zukerberg, L. R., Arnold, A., and Williams, M. E. Immunohistochemical detection and gene amplification of cyclin D1 in mammary infiltrating ductal carcinoma. Mod. Pathol., 9: 725-730, 1996.
16. Nielsen, N. H., Emdin, S. O., Cajander, J., and Landberg, G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene, 14: 295-304, 1997.
17. van Diest, P. J., Michalides, R. J. A. M., Jannink, L., van der Valk, P., Peterse, H. L., de Jong, J. S., Meijer, C. J., and Baak, J. P. Cyclin D1 expression in invasive breast cancer. Correlation and prognostic value. Am. J. Pathol., 150: 705-711, 1997.
18. WAF1 immunohistochemical expression. Int. J. Cancer, 74: 171-174, 1997.
19. Simpson, J. F., Quan, D. E., O'Malley, F., Odom-Maryon, T., and Clarke, P. E. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. Am. J. Pathol., 151: 161-168, 1997.
20. Wani, G., Noyes, I., Milo, G. E., and D'Ambrosio, S. M. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression. Mol. Med., 3: 273-283, 1997.
21. Zhang, S-Y., Caamano, J., Cooper, F., Guo, X., and Klein-Szanto, A. J. P. Immunohistochemistry of cyclin D1 in human breast cancer. Am. J. Clin. Pathol., 102: 695-698, 1994.
22. Weinstat-Saslow, D., Merino, M., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. L., and Steeg, P. S. Overexpression of cyclin D1 mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med., 1: 1257-1260, 1995.
23. Pelosio, P., Barbareschi, M., Bonoldi, E., Marchetti, A., Verderio, P., Caffo, O., Bevilacqua, G., Borracchi, P., Buttitta, F., Barbazza, R., Dalla Palma, P., and Gasparini, G. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann. Oncol., 7: 695-703, 1996.
24. Fantl, V., Richards, M. A., Smith, R., Lammie, G. A., Johnstone, G., Allen, D., Gregory, W., Peters, G., Dickson, C., and Barnes, D. M. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur. J. Cancer, 26: 423-429, 1990.
25. Meyers, S. L., O'Brien, M. T., Smith, T., and Dudley, J. P. Analysis of the int-1, int-int-2, c-myc and neu oncogenes in human breast carcinomas. Cancer Res., 50: 5911-5918, 1990.
26. Borg, A., Sigurdsson, H., Clark, G. M., Ferno, M., Fuqua, S. A. W., Olsson, H., Killander, D., and McGuire, W. L. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br. J. Cancer, 63: 136-142, 1991.
27. Schuuring, E., Verhoeven, E., van Tinteren, H., Peterse, J. L., Nunnink, B., Thunnissen, F. B. J. C., Devilee, P., Cornelisse, C. J., van de Vijver, M. J., Mooi, W. J., and Michalides, R. J. A. M. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res., 52: 5229-5234, 1992.
28. Howell, A., DeFriend, D., and Anderson, E. Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev. Endocrine-Rel. Cancer, 43: 5-21, 1993.
29. 1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinase activation. Oncogene, 12: 753-763, 1996.
30. Weisz, A., Cicatiello, L., Persico, E., Scalona, M., and Bresciani, F. Estrogen stimulates transcription of c-jun protooncogene. Mol. Endocrinol., 4: 1041-1050, 1990.
31. Beato, M., Herrlich, P., and Schutz, G. Steroid hormone receptors: many actors in search of a plot. Cell, 83: 851-857, 1995.
32. Dauvois, S., and Parker, M. G. Mechanism of action of hormone antagonists. In: M. G. Parker (ed.), Frontiers in Molecular Biology, Steroid Hormone Action, pp. 166-185. Oxford, United Kingdom: Oxford University Press, 1993.
33. Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., and Michalides, R. J. A. M. Cdk-independent activation of estrogen receptor by cyclin D1. Cell, 88: 405-415, 1997.
34. Neuman, E., Ladha, M. H., Lin, N., Upton, T. M., Miller, S. J., DiRenzo, J., Pestell, R. G., Hinds, P. W., Dowdy, S. F., Brown, M., and Ewen, M. E. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol. Cell. Biol., 17: 5338-5347, 1997.
35. Weisz, A., and Bresciani, F. Estrogen regulation of proto-oncogenes coding for nuclear proteins. Crit. Rev. Oncog., 4: 361-388, 1993.
36. Planas-Silva, M. D., and Weinberg, R. A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell. Biol., 17: 4059-4069, 1997.
37. Wilcken, N. R. C., Prall, O. W. J., Musgrove, E. A., and Sutherland, R. L. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin. Cancer Res., 3: 849-854, 1997.